ITCI

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -1.85
Percentage change -2.18	%

Peers: LLY REGN GILD VRTX INCY BIIB NBIX BMRN ACAD ALKS

| Held by: VTI VB VXF VBK IBB IWP FBT SCHA IWF IWR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.86	Insider Own	6.54%	Shs Outstand	106.00M	Perf Week	-2.58%
Market Cap	8.81B	Forward P/E	181.82	EPS next Y	0.46	Insider Trans	-6.40%	Shs Float	99.08M	Perf Month	-8.96%
Income	-86.37M	PEG	-	EPS next Q	-0.07	Inst Own	90.73%	Short Float	1.84%	Perf Quarter	11.23%
Sales	613.73M	P/S	14.36	EPS this Y	56.74%	Inst Trans	-0.78%	Short Ratio	3.34	Perf Half Y	20.22%
Book/sh	10.80	P/B	7.70	EPS next Y	172.36%	ROA	-8.46%	Short Interest	1.82M	Perf Year	37.85%
Cash/sh	9.51	P/C	8.74	EPS next 5Y	-	ROE	-9.90%	52W Range	58.92 - 93.45	Perf YTD	16.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	12.47%	ROI	-7.46%	52W High	-11.06%	Beta	0.70
Dividend TTM	-	Quick Ratio	7.51	Sales past 5Y	7617.73%	Gross Margin	92.30%	52W Low	41.04%	ATR (14)	2.23
Dividend Ex-Date	-	Current Ratio	7.66	EPS Y/Y TTM	47.14%	Oper. Margin	-19.82%	RSI (14)	45.29	Volatility	2.42% 2.56%
Employees	610	Debt/Eq	0.02	Sales Y/Y TTM	46.08%	Profit Margin	-14.07%	Recom	1.41	Target Price	101.87
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	1.35%	Payout	-	Rel Volume	0.58	Prev Close	84.96
Sales Surprise	1.78%	EPS Surprise	-39.51%	Sales Q/Q	39.00%	Earnings	Oct 30 BMO	Avg Volume	545.28K	Price	83.11
SMA20	-2.68%	SMA50	1.97%	SMA200	12.25%	Trades		Volume	318,297	Change	-2.18%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-06-24	Upgrade	Piper Sandler	Neutral → Overweight	$68 → $92
Jan-03-24	Initiated	Robert W. Baird	Outperform	$83
Dec-11-23	Initiated	TD Cowen	Outperform	$75
Apr-20-23	Initiated	Morgan Stanley	Overweight	$80
Aug-22-22	Downgrade	Goldman	Buy → Neutral	$64 → $49
Jul-07-22	Initiated	Mizuho	Buy	$74
Jun-14-22	Initiated	UBS	Buy	$75
Apr-22-22	Initiated	Piper Sandler	Neutral	$59
Feb-16-22	Initiated	Goldman	Buy	$64
Sep-23-21	Initiated	Needham	Buy	$55
Dec-15-20	Initiated	BofA Securities	Buy	$40
Dec-10-20	Initiated	Goldman	Buy	$38
Feb-20-20	Initiated	Evercore ISI	Outperform
Jan-31-20	Downgrade	JP Morgan	Overweight → Neutral	$26
Dec-24-19	Reiterated	Canaccord Genuity	Buy	$29 → $65
Aug-12-19	Initiated	Jefferies	Buy	$16
Feb-26-18	Initiated	JP Morgan	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform	$33
Dec-15-17	Initiated	Canaccord Genuity	Buy	$31
Nov-08-17	Upgrade	SunTrust	Hold → Buy

Show Previous Ratings

Dec-03-24 07:30AM	Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy (GlobeNewswire)
Nov-29-24 11:31AM	Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report? (Zacks)
Nov-27-24 06:00AM	How Intra-Cellular surprised Wall Street by breaking character (BioPharma Dive)
Nov-19-24 08:00AM	Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 08:00AM	Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress (GlobeNewswire)
01:07PM	Loading…
Nov-06-24 01:07PM	Intra-Cellular bolsters Caplyta data with another Phase III win (Pharmaceutical Technology)
Nov-05-24 07:00AM	Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia (GlobeNewswire)
Oct-31-24 03:07AM	Intra-Cellular Therapies Inc (ITCI) Q3 2024 Earnings Call Highlights: Robust Sales Growth and ... (GuruFocus.com)
Oct-30-24 08:40AM	Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +11.36%
07:40AM	Intra-Cellular: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance (GlobeNewswire)
Oct-29-24 09:05AM	What To Expect From Intra-Cellular Therapies Inc (ITCI) Q3 2024 Earnings (GuruFocus.com)
Oct-23-24 10:01AM	Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-17-24 08:00AM	Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire)
Oct-13-24 07:23PM	Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds (Insider Monkey)
03:05PM	Loading…
Oct-10-24 03:05PM	JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc (GuruFocus.com)
Sep-23-24 08:00AM	Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress (GlobeNewswire)
Sep-06-24 11:31AM	Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report? (Zacks)
Sep-05-24 01:12AM	Intra-Cellular Therapies, Inc. (ITCI): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-28-24 08:00AM	Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 11:06AM	Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon (Investor's Business Daily)
09:54AM	Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat (Zacks)
08:00AM	Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Aug-07-24 04:14PM	Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' (Investor's Business Daily) -5.81%
08:45AM	Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:41AM	Intra-Cellular: Q2 Earnings Snapshot (Associated Press Finance)
07:40AM	Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer (GlobeNewswire)
07:30AM	Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance (GlobeNewswire)
Jul-31-24 10:01AM	Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	Loading…
Jul-24-24 08:00AM	Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire)
Jul-09-24 09:55AM	Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High? (Zacks)
Jun-24-24 09:52AM	Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe (Zacks)
Jun-20-24 02:37PM	Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 (Investor's Business Daily)
Jun-19-24 10:27AM	Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals (Zacks)
06:27AM	Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock? (Zacks)
Jun-18-24 04:22PM	Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win (Investor's Business Daily) +9.60%
01:34PM	Intra-Cellular Therapies edges closer to FDA win for Caplyta in depression (Clinical Trials Arena)
07:30AM	Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder (GlobeNewswire)
07:30AM	Intra-Cellular depression drug succeeds in second late-stage study (BioPharma Dive)
Jun-10-24 08:00AM	Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
Jun-06-24 11:31AM	Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report? (Zacks)
May-30-24 06:00AM	The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio (InvestorPlace)
May-29-24 08:00AM	Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-27-24 06:34PM	Hedge Funds Like Intra-Cellular Therapies (NASDAQ:ITCI) (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
May-23-24 08:00AM	Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting (GlobeNewswire)
May-08-24 03:44PM	Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.91%
11:43AM	Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates (Zacks)
08:00AM	Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
03:13AM	Intra-Cellular Therapies Inc (ITCI) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ... (GuruFocus.com)
May-07-24 09:18AM	Sector Update: Health Care Stocks Steady Pre-Bell Tuesday (MT Newswires)
09:12AM	Intra-Cellular Therapies Surpasses Q1 Revenue Estimates with Strong CAPLYTA Sales (GuruFocus.com)
08:40AM	Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:16AM	Intra-Cellular Therapies' Q1 Net Loss Narrows, Net Total Revenue Rises (MT Newswires)
07:37AM	Intra-Cellular: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Intra-Cellular Therapies Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 08:00AM	Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire)
Apr-25-24 10:01AM	Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-24-24 04:01PM	Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
11:36AM	3 Biotech Stocks With Skyrocketing Potential: April 2024 (InvestorPlace)
11:31AM	Alexandria Real Estate Equities, Inc. (NYSE:ARE) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-22-24 11:10AM	10 Best Performing Biotech ETFs in 2024 (Insider Monkey)
Apr-17-24 08:46PM	Intra-Cellular Therapies Prices Public Offering of Common Stock (GlobeNewswire) -6.12%
09:44AM	Biotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy Point (Investor's Business Daily)
09:21AM	Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals (Zacks)
07:36AM	Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last? (Zacks)
Apr-16-24 04:06PM	Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock (GlobeNewswire) +23.29%
04:00PM	Intra-Cellular Launches 23% To Record High, Breaking Out After Depression Drug Scores Big (Investor's Business Daily)
12:19PM	UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall, Tuesday, 4/16/2024 (Associated Press)
09:08AM	Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results (Investor's Business Daily)
07:14AM	Intra-Cellular builds case for depression drug with late-stage trial win (BioPharma Dive)
07:00AM	Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder (GlobeNewswire)
Mar-19-24 08:30AM	Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes (GlobeNewswire)
Mar-12-24 01:16AM	Intra-Cellular Therapies Inc Chairman, President & CEO Sharon Mates Sells 61,277 Shares (GuruFocus.com)
Mar-06-24 08:00AM	Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey) -5.96%
Feb-28-24 05:01AM	EVP and General Counsel Michael Halstead Sells Shares of Intra-Cellular Therapies Inc (GuruFocus.com)
Feb-27-24 08:00AM	Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-23-24 11:59AM	Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:41AM	Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss (Zacks)
Feb-22-24 07:59AM	Intra-Cellular: Q4 Earnings Snapshot (Associated Press Finance)
07:53AM	Intra-Cellular Therapies Inc (ITCI) Reports Robust Revenue Growth in 2023 Earnings (GuruFocus.com)
07:30AM	Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update (GlobeNewswire)
Feb-15-24 10:00AM	Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-13-24 11:51AM	Biotech Leader Intra-Cellular Therapies Nears Buy Point Ahead Of Earnings Report (Investor's Business Daily)
Feb-10-24 03:07PM	Stock Market Today: Nasdaq Hot, But Watch Out For This; Cathie Wood Play Leads 5 New Buys (Investor's Business Daily)
Feb-08-24 08:00AM	Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast (GlobeNewswire)
Feb-05-24 11:11PM	Intra-Cellular Therapies Inc EVP, Chief Medical Officer Suresh Durgam Sells 6,167 Shares (GuruFocus.com)
Jan-18-24 09:01PM	Intra-Cellular Therapies Inc CEO Sharon Mates Sells 191,362 Shares (GuruFocus.com)
Jan-12-24 07:02PM	Intra-Cellular Therapies Inc EVP and General Counsel Michael Halstead Sells 50,000 Shares (GuruFocus.com)
09:23AM	16 Best Mid-Cap Growth Stocks To Buy Now (Insider Monkey)
Jan-05-24 11:02AM	Intra-Cellular Therapies Inc EVP Suresh Durgam Sells 62,282 Shares (GuruFocus.com)
Jan-02-24 08:00AM	Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-01-24 09:55AM	Intra-Cellular Therapies (ITCI) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey)
Dec-19-23 12:00PM	Intra-Cellular Therapies (ITCI) is a Great Momentum Stock: Should You Buy? (Zacks)
Dec-16-23 03:02PM	Intra-Cellular Therapies Inc's EVP, Chief Medical Officer Suresh Durgam Sells 21,262 Shares (GuruFocus.com)
Dec-13-23 01:11PM	IBD 50 Stocks To Watch: Biotech Leader Intra-Cellular Therapies Is Breaking Out Past A New Buy Point (Investor's Business Daily)
Dec-05-23 08:00AM	Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting (GlobeNewswire)

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mates Sharon	Chairman and CEO	Dec 05 '24	Option Exercise	12.73	51,697	658,103	1,122,026	Dec 06 06:01 PM
Mates Sharon	Chairman and CEO	Dec 04 '24	Option Exercise	12.73	51,000	649,230	1,121,329	Dec 06 06:01 PM
Mates Sharon	Chairman and CEO	Dec 04 '24	Sale	85.80	51,000	4,375,659	1,070,329	Dec 06 06:01 PM
Mates Sharon	Chairman and CEO	Dec 05 '24	Sale	84.08	51,697	4,346,842	1,070,329	Dec 06 06:01 PM
Mates Sharon	Officer	Dec 05 '24	Proposed Sale	84.02	51,697	4,343,616		Dec 05 04:27 PM
Mates Sharon	Officer	Dec 04 '24	Proposed Sale	85.73	51,000	4,372,478		Dec 04 04:18 PM
Halstead Michael	President	Nov 13 '24	Option Exercise	36.89	18,714	690,359	18,714	Nov 14 06:01 PM
Halstead Michael	President	Nov 12 '24	Option Exercise	23.94	22,869	547,484	22,869	Nov 14 06:01 PM
Halstead Michael	President	Nov 12 '24	Sale	89.12	22,869	2,038,079	0	Nov 14 06:01 PM
Halstead Michael	President	Nov 13 '24	Sale	88.38	18,714	1,654,021	0	Nov 14 06:01 PM
Halstead Michael	Officer	Nov 12 '24	Proposed Sale	89.08	41,583	3,704,223		Nov 12 04:28 PM
ALEXANDRIA VENTURE INVESTMENTS	Director	Sep 06 '24	Proposed Sale	73.17	25,000	1,829,178		Sep 06 05:43 PM
Mates Sharon	Chairman and CEO	Aug 29 '24	Option Exercise	12.73	35,604	453,239	1,105,933	Aug 30 06:01 PM
Mates Sharon	Chairman and CEO	Aug 30 '24	Option Exercise	12.73	34,396	437,861	1,104,725	Aug 30 06:01 PM
Mates Sharon	Chairman and CEO	Aug 29 '24	Sale	72.57	35,604	2,583,884	1,070,329	Aug 30 06:01 PM
Mates Sharon	Chairman and CEO	Aug 30 '24	Sale	72.84	34,396	2,505,351	1,070,329	Aug 30 06:01 PM
Mates Sharon	Officer	Aug 30 '24	Proposed Sale	72.78	34,396	2,503,218		Aug 30 04:06 PM
Mates Sharon	Officer	Aug 29 '24	Proposed Sale	72.51	35,604	2,581,677		Aug 29 04:34 PM
Mates Sharon	Chairman and CEO	Aug 27 '24	Option Exercise	17.57	40,513	711,813	1,110,842	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 28 '24	Option Exercise	17.57	32,699	574,521	1,103,028	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 26 '24	Option Exercise	17.57	22,713	399,067	1,093,042	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 27 '24	Sale	73.58	40,513	2,981,056	1,070,329	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 28 '24	Sale	72.75	32,699	2,378,801	1,070,329	Aug 28 06:00 PM
Mates Sharon	Chairman and CEO	Aug 26 '24	Sale	74.59	22,713	1,694,229	1,070,329	Aug 28 06:00 PM
Mates Sharon	Officer	Aug 28 '24	Proposed Sale	72.69	32,699	2,376,774		Aug 28 04:34 PM
Mates Sharon	Officer	Aug 27 '24	Proposed Sale	73.52	40,513	2,978,542		Aug 27 04:22 PM
Mates Sharon	Officer	Aug 26 '24	Proposed Sale	74.53	22,713	1,692,819		Aug 26 04:36 PM
Mates Sharon	Chairman and CEO	Aug 21 '24	Option Exercise	17.57	53,013	931,438	1,123,342	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 22 '24	Option Exercise	17.57	39,380	691,907	1,109,709	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 23 '24	Option Exercise	17.57	28,680	503,908	1,099,009	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 21 '24	Sale	75.65	53,013	4,010,501	1,070,329	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 22 '24	Sale	74.68	39,380	2,940,802	1,070,329	Aug 23 06:00 PM
Mates Sharon	Chairman and CEO	Aug 23 '24	Sale	74.46	28,680	2,135,435	1,070,329	Aug 23 06:00 PM
Mates Sharon	Officer	Aug 23 '24	Proposed Sale	74.40	28,680	2,133,656		Aug 23 04:14 PM
Mates Sharon	Officer	Aug 22 '24	Proposed Sale	74.62	39,380	2,938,358		Aug 22 04:09 PM
Mates Sharon	Officer	Aug 21 '24	Proposed Sale	75.59	53,013	4,007,208		Aug 21 04:25 PM
Neumann Mark	EVP, Chief Commercial Officer	Aug 16 '24	Option Exercise	36.89	18,714	690,359	48,414	Aug 20 06:03 PM
Neumann Mark	EVP, Chief Commercial Officer	Aug 16 '24	Sale	75.08	18,714	1,405,047	29,700	Aug 20 06:03 PM
Neumann Mark	Officer	Aug 16 '24	Proposed Sale	75.02	18,714	1,403,972		Aug 16 04:04 PM
RIGGS RORY B	Director	Jun 24 '24	Option Exercise	16.86	20,000	337,200	121,062	Jun 25 06:04 PM
RIGGS RORY B	Director	Jun 24 '24	Sale	75.57	4,462	337,193	116,600	Jun 25 06:04 PM
VAN NOSTRAND ROBERT L	Director	Jun 18 '24	Option Exercise	16.86	20,000	337,200	29,690	Jun 21 06:00 PM
VAN NOSTRAND ROBERT L	Director	Jun 18 '24	Sale	75.91	20,000	1,518,199	9,690	Jun 21 06:00 PM
Mates Sharon	Chairman and CEO	Apr 24 '24	Option Exercise	17.26	20,020	345,618	1,070,329	Apr 25 05:08 PM
RIGGS RORY B	Director	Mar 20 '24	Option Exercise	18.56	20,000	371,200	99,235	Mar 22 04:12 PM
Mates Sharon	Chairman, President & CEO	Mar 07 '24	Sale	66.50	40,712	2,707,277	1,050,309	Mar 11 08:33 PM
Mates Sharon	Chairman, President & CEO	Mar 11 '24	Sale	65.21	20,565	1,341,123	1,050,309	Mar 11 08:33 PM
Hineline Lawrence J.	SVP of Finance, CFO	Mar 10 '24	Option Exercise	56.73	4,539	257,497	4,539	Mar 11 08:33 PM
Hineline Lawrence J.	SVP of Finance, CFO	Mar 07 '24	Sale	66.60	13,132	874,560	0	Mar 11 08:33 PM
Hineline Lawrence J.	SVP of Finance, CFO	Mar 11 '24	Sale	65.96	10,121	667,587	0	Mar 11 08:33 PM
Halstead Michael	EVP and General Counsel	Mar 07 '24	Sale	66.15	13,132	868,698	0	Mar 11 08:32 PM
Halstead Michael	EVP and General Counsel	Mar 11 '24	Sale	65.97	7,345	484,537	0	Mar 11 08:32 PM
Neumann Mark	EVP, Chief Commercial Officer	Mar 07 '24	Sale	66.57	13,132	874,179	29,700	Mar 11 08:31 PM
Neumann Mark	EVP, Chief Commercial Officer	Mar 11 '24	Sale	65.61	7,345	481,931	29,700	Mar 11 08:31 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Mar 07 '24	Sale	66.56	6,450	429,308	16,170	Mar 11 08:31 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Mar 11 '24	Sale	65.59	3,712	243,482	19,803	Mar 11 08:31 PM
VAN NOSTRAND ROBERT L	Director	Feb 27 '24	Option Exercise	18.56	20,000	371,200	29,611	Feb 28 07:41 PM
VAN NOSTRAND ROBERT L	Director	Feb 27 '24	Sale	72.93	20,000	1,458,650	9,611	Feb 28 07:41 PM
Halstead Michael	EVP and General Counsel	Feb 26 '24	Sale	69.53	7,907	549,784	0	Feb 27 08:00 PM
Hineline Lawrence J.	SVP of Finance, CFO	Feb 26 '24	Option Exercise	36.89	5,882	216,987	5,882	Feb 27 08:00 PM
Hineline Lawrence J.	SVP of Finance, CFO	Feb 26 '24	Sale	69.43	13,337	925,961	0	Feb 27 08:00 PM
Mates Sharon	Chairman, President & CEO	Feb 26 '24	Sale	69.79	22,590	1,576,464	1,050,309	Feb 27 07:59 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Feb 26 '24	Sale	70.17	4,112	288,534	9,488	Feb 27 07:58 PM
Neumann Mark	EVP, Chief Commercial Officer	Feb 26 '24	Sale	70.13	7,907	554,491	29,700	Feb 27 07:58 PM
MARCUS JOEL S	Director	Feb 26 '24	Option Exercise	48.93	36,757	1,798,678	65,990	Feb 27 07:57 PM
MARCUS JOEL S	Director	Feb 26 '24	Sale	68.68	26,328	1,808,253	39,662	Feb 27 07:57 PM
Halstead Michael	EVP and General Counsel	Feb 02 '24	Sale	66.42	11,860	787,719	0	Feb 05 06:13 PM
Mates Sharon	Chairman, President & CEO	Feb 02 '24	Sale	67.07	33,885	2,272,694	1,050,309	Feb 05 06:10 PM
Neumann Mark	EVP, Chief Commercial Officer	Feb 02 '24	Sale	67.15	11,860	796,367	29,700	Feb 05 06:07 PM
Hineline Lawrence J.	SVP of Finance, CFO	Feb 02 '24	Sale	66.62	11,183	745,037	0	Feb 05 06:05 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Feb 02 '24	Sale	67.19	6,167	414,355	5,693	Feb 05 06:02 PM
Mates Sharon	Chairman, President & CEO	Jan 16 '24	Option Exercise	16.86	75,361	1,270,586	1,125,670	Jan 18 07:47 PM
Mates Sharon	Chairman, President & CEO	Jan 18 '24	Option Exercise	16.86	67,917	1,145,081	1,118,226	Jan 18 07:47 PM
Mates Sharon	Chairman, President & CEO	Jan 17 '24	Option Exercise	16.86	48,084	810,696	1,098,393	Jan 18 07:47 PM
Mates Sharon	Chairman, President & CEO	Jan 16 '24	Sale	67.25	75,361	5,067,982	1,050,309	Jan 18 07:47 PM
Mates Sharon	Chairman, President & CEO	Jan 18 '24	Sale	65.19	67,917	4,427,848	1,050,309	Jan 18 07:47 PM
Mates Sharon	Chairman, President & CEO	Jan 17 '24	Sale	66.24	48,084	3,185,062	1,050,309	Jan 18 07:47 PM
Halstead Michael	EVP and General Counsel	Jan 11 '24	Option Exercise	13.60	50,000	680,051	50,000	Jan 12 06:02 PM
Halstead Michael	EVP and General Counsel	Jan 11 '24	Sale	66.83	50,000	3,341,699	0	Jan 12 06:02 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Jan 02 '24	Option Exercise	19.87	62,282	1,237,543	62,282	Jan 04 07:54 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Jan 02 '24	Sale	70.60	62,282	4,397,113	0	Jan 04 07:54 PM
Durgam Suresh K.	EVP, Chief Medical Officer	Dec 13 '23	Sale	65.00	21,262	1,382,030	0	Dec 15 05:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Intra-Cellular Therapies Inc

Upgrade your FINVIZ experience